Moderna, Inc.

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 08/10/2024 BST			Pre-market 14:00:56
58.39 ^USD	-0.56%		58.44	+0.09%

02:16pm	Redburn Atlantic Adjusts Moderna's Price Target to $73 From $102, Keeps Neutral Rating	MT
11:47am	Analyst recommendations: Blackstone, Exxon Mobil, Morningstar, Fair Isac, Moderna...

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Vous êtes déja client ? Log In

Latest news about Moderna, Inc.

Redburn Atlantic Adjusts Moderna's Price Target to $73 From $102, Keeps Neutral Rating	01:16pm	MT
Analyst recommendations: Blackstone, Exxon Mobil, Morningstar, Fair Isac, Moderna...	10:47am
GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up	10-08	RE
Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents	10-08	RE
Goldman Sachs Adjusts Price Target on Moderna to $130 From $139	10-04	MT
Evercore ISI Adjusts Price Target on Moderna to $120 From $105, Maintains In Line	10-02	MT
Moderna: Abbas Hussain joins the Board of Directors	10-02	CF
Moderna, Inc. Appoints Abbas Hussain to Board of Directors	10-02	CI
Moderna: agreement with Cenra Healthcare in Taiwan	10-01	CF
Moderna: testing an experimental vaccine against norovirus	10-01	CF
Moderna, Cenra Agree on Promotion of Vaccines in Taiwan	10-01	MT
Moderna, Inc. and Cenra Healthcare Enter Joint Agreement to Promote Moderna's mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines	09-30	CI
Moderna Doses First Participant in Phase 3 Trial of Potential Norovirus Vaccine	09-30	MT
Moderna Begins Late-stage Study of Norovirus Vaccine Candidate	09-30	MT
Klotho Neurosciences, Inc. Appoints Robert Langer to Its Scientific Advisory Board	09-30	CI
Pfizer, Moderna and BioNTech take patent fight to Court of Appeal	09-25	AN
Pfizer v Moderna COVID vaccine patents battle to go to appeal in UK	09-25	RE
Deutsche Bank Cuts Moderna Price Target to $75 From $80	09-20	MT
Dow, S&P 500 Close at Record Highs	09-19	MT
Dow, S&P 500 Close at Record Highs	09-19	MT
Dow, S&P 500 Little Changed Ahead of Fed Decision	09-17	MT
Dow, S&P 500 Close Little Changed Ahead of Fed Decision	09-17	MT
US Equities Markets End Mixed Tuesday as Investors Parse Macro Data, Await Fed Decision	09-17	MT
Sector Update: Health Care Stocks Retreat Late Afternoon	09-17	MT
Equities Mixed Intraday as Traders Weigh Macro Data, Await Fed Decision	09-17	MT

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (97.4%); - grant revenue (1.4%); - revenue from collaboration agreements (1.2%). At the end of 2023, the group possessed a portfolio of 41 products in clinical development, of which 6 in phase III, 12 in phase II and 18 in phase I, and 5 products in preclinical development. Net sales are distributed geographically as follows: the United States (27.7%), Europe (19.8%) and other (52.5%).

Employees

5,600

Sector

Biotechnology & Medical Research

Calendar

30/10/2024 - Q3 2024 Earnings Release (Projected)

More about the company